Personalized Thera(g)nostic Approach in Patients with Pheochromocytoma and Paraganglioma: 131I-mIBG and/or Peptide Receptor Radionuclide Therapy

被引：0
|
作者：
Svirydenka, H. [1 ]
Nilica, B. [1 ]
Mair, C. [1 ]
Rossetti, L. [1 ]
Kroiss, A. [1 ]
Di Santo, G. [1 ]
Buxbaum, S. [1 ]
Decristoforo, C. [1 ]
Uprimny, C. [1 ]
Gabriel, M. [1 ]
Virgolini, I. [1 ]
机构：
[1] Univ Klin Nukl Med, Innsbruck, Austria
来源：
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING | 2020年 / 47卷 / SUPPL 1期
关键词：
D O I：
暂无
中图分类号：
R8 [特种医学]; R445 [影像诊断学];
学科分类号：
1002 ; 100207 ; 1009 ;
摘要：
OP-563
引用
收藏
页码：S278 / S278
页数：1
相关论文
共 50 条
  • [1] 131I-metaiodobenzylguanidine and peptide receptor radionuclide therapy in pheochromocytoma and paraganglioma
    Jungels, Christiane
    Karfis, Ioannis
    CURRENT OPINION IN ONCOLOGY, 2021, 33 (01) : 33 - 39
  • [2] 131I-MIBG Therapy in metastatic phaeochromocytoma and paraganglioma
    Gedik, Gonca Kara
    Hoefnagel, Cornelis A.
    Bais, Evert
    Olmos, Renato A. Valdes
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2008, 35 (04) : 725 - 733
  • [3] Adverse Prognostic Factors in Patients Refractory Pheochromocytoma and Paraganglioma After 131I-metaiodinebenzylguanidine (131I-mIBG) Therapy
    Hiromasa, T.
    Wakabayashi, H.
    Kayano, D.
    Inaki, A.
    Toratani, A.
    Akatani, N.
    Watanabe, S.
    Yamase, T.
    Kunita, Y.
    Mori, H.
    Saito, S.
    Takata, A.
    Kinuya, S.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2021, 48 (SUPPL 1) : S568 - S569
  • [4] 131I-MIBG Therapy in metastatic phaeochromocytoma and paraganglioma
    Gonca Kara Gedik
    Cornelis A. Hoefnagel
    Evert Bais
    Renato A. Valdés Olmos
    European Journal of Nuclear Medicine and Molecular Imaging, 2008, 35 : 725 - 733
  • [5] I-131 MIBG therapy in patients with malignant pheochromocytoma and paraganglioma
    Gedik, G. K.
    Hoefnagel, C. A.
    Bais, E.
    Olmos, R. A. Valdes
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2007, 34 : S241 - S241
  • [6] Efficacy and Safety of High-Specific-Activity 131I-MIBG Therapy in Patients with Advanced Pheochromocytoma or Paraganglioma
    Pryma, Daniel A.
    Chin, Bennett B.
    Noto, Richard B.
    Dillon, Joseph S.
    Perkins, Stephanie
    Solnes, Lilja
    Kostakoglu, Lale
    Serafini, Aldo N.
    Pampaloni, Miguel H.
    Jensen, Jessica
    Armor, Thomas
    Lin, Tess
    White, Theresa
    Stambler, Nancy
    Apfel, Stuart
    DiPippo, Vincent A.
    Mahmood, Syed
    Wong, Vivien
    Jimenez, Camilo
    JOURNAL OF NUCLEAR MEDICINE, 2019, 60 (05) : 623 - 630
  • [7] 131I-MIBG negative progressive symptomatic metastatic paraganglioma: response and outcome with 177Lu-DOTATATE peptide receptor radionuclide therapy
    Parghane, Rahul V.
    Talole, Sanjay
    Basu, Sandip
    ANNALS OF NUCLEAR MEDICINE, 2021, 35 (01) : 92 - 101
  • [8] 131I-MIBG negative progressive symptomatic metastatic paraganglioma: response and outcome with 177Lu-DOTATATE peptide receptor radionuclide therapy
    Rahul V. Parghane
    Sanjay Talole
    Sandip Basu
    Annals of Nuclear Medicine, 2021, 35 : 92 - 101
  • [9] External Beam Radiation Therapy With or Without 131I-MIBG Systemic Radiation Therapy in the Therapy Of Patients With Malignant Pheochromocytoma and Paraganglioma
    Cengel, K. A.
    Lauren, F.
    Alonso-Basanta, M.
    Pryma, D.
    Simone, C. B.
    Findlay, J.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2013, 87 (02): : S615 - S616
  • [10] 131I-MIBG treatment in patients with metastatic paraganglioma and pheocrhomocytoma
    Bernal, J.
    Prado, S.
    Agudelo, M.
    Utrera, A.
    Canon, J.
    Bello, P.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2020, 47 (SUPPL 1) : S690 - S690
12345